Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

High plasma GFAP level predicts disability accumulation in secondary progressive MS

Key clinical point: High blood glial fibrillary acidic protein level is associated with increased risk of restriction to a wheelchair.

Major finding: Overall, approximately 12% of patients with a high glial fibrillary acidic protein level attained an Expanded Disability Status Scale score of 7, compared with about 5% of patients with a low GFAP level.

Study details: A post hoc analysis of 1,405 participants with secondary progressive multiple sclerosis in the EXPAND study.

Disclosures: Study funding was not reported. Dr. Kuhle had no relevant disclosures to report.


Kuhle J et al. MSVirtual2020.